Tirzepatide is the first in a class of drugs called dual GLP-1/GIP receptor agonists that activate the receptor for another gut hormone, glucose-dependent insulinotropic polypeptide (GIP), in addition to the GLP-1 receptor
Ueda P, Wintzell V, Melbye M, Eliasson B, Svensson A-M, Franzn S, et al
We were unable to identify any current clinical trials exploring ghrelin antagonism under progress, though recently ghrelin receptor inverse agonists have been successfully profiled in humans [93]
Contraindications and Precautions GLP-1 agonists are contraindicated in individuals with hypersensitivity to these medications and those who are pregnant (48)
While Asia is capturing high-growth tailwinds, OECD markets remain steady but more regulated, requiring adaptive commercialization across channels, especially where Rx-OTC hybrid categories are evolving
When a promising molecule surfaces, scientists must decode its exact mechanism (which receptor it binds to, which pathway it activates or blocks) and then modify the raw peptide to make it stable enough for human use